Contract 75A50124C00018
Red Queen Therapeutics Inc. · Department Of Health And Human Services · June 25, 2024
Red Queen Therapeutics Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on June 25, 2024 for $267,000 (current value) of work in research and development in biotechnology (except nanobiotechnology). Performance is in Cambridge, MA. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on October 29, 2025. If all options are exercised, the contract could reach $267,000.
Contract details
- PIID
- 75A50124C00018
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- Cambridge, MA
- First action
- June 25, 2024
- Latest action
- October 29, 2025
Description
RED QUEEN THERAPEUTICS, INC - AOI#25(FASTX) R&D FOR RAPID RESPONSE PLATFORM FOR THE DEVELOPMENT OF A PAN-INFLUENZA VIRUS FUSION INHIBITOR FOR THE TREATMENT OF INFLUENZA VIRUS INFECTIONS
Modification timeline
-
October 29, 2025Mod P00002 · Close Out$266.5K
-
June 25, 2024Mod P00001 · Other Administrative Action$750.0K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50124C00018?
Contract 75A50124C00018 is a federal contract awarded to Red Queen Therapeutics Inc. by Department Of Health And Human Services on June 25, 2024 for $267,000 of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 1 time since the base award.
Who won contract 75A50124C00018?
Red Queen Therapeutics Inc. won contract 75A50124C00018 from Department Of Health And Human Services.
How much is contract 75A50124C00018 worth?
Contract 75A50124C00018 has obligated $0 to date but carries a potential ceiling of $267,000 if fully funded and all options are exercised.